Merck KGaA's Lupus Drug Gets US FDA Breakthrough Therapy Designation
() -- The US Food and Drug Administration granted breakthrough therapy designation to Merck KGaA's (MRK.F) enpatoran for the treatment of lupus with active cutaneous manifestations. The designation for the German science and technology company's oral selective toll-like receptor 7/8 inhibitor is supported by results fr